Literature DB >> 25833703

Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension.

O Petrák1, T Zelinka1, B Štrauch1, J Rosa1, Z Šomlóová1, T Indra1, H Turková1, R Holaj1, J Widimský1.   

Abstract

The aim of the study was to analyze the clinical use of different types of combination therapy in a large sample of consecutive patients with uncontrolled hypertension referred to Hypertension Centre. We performed a retrospective analysis of combination antihypertensive therapy in 1254 consecutive patients with uncontrolled hypertension receiving at least triple-combination antihypertensive therapy. Among the most prescribed antihypertensive classes were renin-angiotensin blockers (96.8%), calcium channel blockers (82.5%), diuretics (82.0%), beta-blockers (73.0%), centrally acting drugs (56.0%) and urapidil (24.1%). Least prescribed were spironolactone (22.2%) and alpha-1-blockers (17.1%). Thiazide/thiazide-like diuretics were underdosed in more than two-thirds of patients. Furosemide was prescribed in 14.3% of patients treated with diuretics, while only indicated in 3.9%. Inappropriate combination therapy was found in 40.4% of patients. Controversial dual and higher blockade of renin-angiotensin system occurred in 25.2%. Incorrect use of a combination of two antihypertensive drugs with the similar mechanism of action was found in 28.1%, most commonly a combination of two drugs with central mechanism (13.5%). In conclusion, use of controversial or incorrect combinations of drugs in uncontrolled hypertension is common. Diuretics are frequently underdosed and spironolactone remains neglected in general practice. The improper combination of antihypertensive drugs may contribute to uncontrolled hypertension.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25833703     DOI: 10.1038/jhh.2015.24

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  29 in total

Review 1.  Use of diuretics in patients with hypertension.

Authors:  Michael E Ernst; Marvin Moser
Journal:  N Engl J Med       Date:  2009-11-26       Impact factor: 91.245

Review 2.  Combination of loop diuretics with thiazide-type diuretics in heart failure.

Authors:  Jacob C Jentzer; Tracy A DeWald; Adrian F Hernandez
Journal:  J Am Coll Cardiol       Date:  2010-11-02       Impact factor: 24.094

3.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

4.  Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.

Authors:  Jan Václavík; Richard Sedlák; Martin Plachy; Karel Navrátil; Jirí Plásek; Jirí Jarkovsky; Tomás Václavík; Roman Husár; Eva Kociánová; Milos Táborsky
Journal:  Hypertension       Date:  2011-05-02       Impact factor: 10.190

5.  Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

Authors:  Leszek Tylicki; Przemysław Rutkowski; Marcin Renke; Wojciech Larczyński; Ewa Aleksandrowicz; Wiesława Lysiak-Szydlowska; Bolesław Rutkowski
Journal:  Am J Kidney Dis       Date:  2008-04-18       Impact factor: 8.860

6.  Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.

Authors:  Yoshiyuki Furumatsu; Yasuyuki Nagasawa; Kodo Tomida; Satoshi Mikami; Tetsuya Kaneko; Noriyuki Okada; Yoshiharu Tsubakihara; Enyu Imai; Tatsuya Shoji
Journal:  Hypertens Res       Date:  2008-01       Impact factor: 3.872

7.  Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region.

Authors:  B Strauch; T Zelinka; M Hampf; R Bernhardt; J Widimsky
Journal:  J Hum Hypertens       Date:  2003-05       Impact factor: 3.012

8.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.

Authors:  Neil Chapman; Choon Lan Chang; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Journal:  Circulation       Date:  2008-06-16       Impact factor: 29.690

10.  Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).

Authors:  Enyu Imai; Masakazu Haneda; Tetsu Yamasaki; Fumiaki Kobayashi; Atsushi Harada; Sadayoshi Ito; Juliana C N Chan; Hirofumi Makino
Journal:  Hypertens Res       Date:  2013-09-12       Impact factor: 3.872

View more
  5 in total

1.  Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.

Authors:  Oyunbileg Magvanjav; Rhonda M Cooper-Dehoff; Caitrin W McDonough; Yan Gong; William R Hogan; Julie A Johnson
Journal:  Am J Hypertens       Date:  2020-04-01       Impact factor: 2.689

Review 2.  Should All Patients with Resistant Hypertension Receive Spironolactone?

Authors:  Ján Rosa; Tomáš Zelinka; Ondřej Petrák; Branislav Štrauch; Robert Holaj; Jiří Widimský
Journal:  Curr Hypertens Rep       Date:  2016-11       Impact factor: 5.369

3.  Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO Observational Studies.

Authors:  Csaba András Dézsi; Maria Glezer; Yuri Karpov; Romualda Brzozowska-Villatte; Csaba Farsang
Journal:  Adv Ther       Date:  2020-11-05       Impact factor: 3.845

4.  Comparison of 24-Hour Ambulatory Central Blood Pressure Reduction Efficacy Between Fixed Amlodipine or Up-Titrated Hydrochlorothiazide Plus Losartan: The K-Central Study.

Authors:  Eun Joo Cho; Hae Young Lee; Ki Chul Sung; Sungha Park; Il-Suk Sohn; Chang Gyu Park; Dong-Ju Choi; Jong Won Ha; Young Keun Ahn; Jinho Shin; Soon-Jun Hong; Soon Kil Kim; Wook-Jin Chung; Byung Su Yoo; Taek Jong Hong; Ho Joong Youn; Myeong-Chan Cho; Shung Chull Chae; Young Jo Kim; Chong-Jin Kim
Journal:  Am J Hypertens       Date:  2019-09-24       Impact factor: 2.689

5.  Cross-sectional survey evaluating blood pressure control ACHIEVEment in hypertensive patients treated with multiple anti-hypertensive agents in Belgium and Luxembourg.

Authors:  Marc Leeman; Michèle Dramaix; Bregt Van Nieuwenhuyse; Josse R Thomas
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.